A systematic review of the role of adjuvant and neoadjuvant pharmacotherapy in patients undergoing radical prostatectomy

Bibliography

• Jemal A, Siegel R, Xu J, Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300
   PubMed Web of Science ®Google Scholar
• D'Amico AV, Whittington R, Malkowicz SB, Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-74
   PubMed Web of Science ®Google Scholar
• Shao YH, Demissie K, Shih W, Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst 2009;101:1280-3
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Bellmunt J, Bolla M, EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011;59:61-71
   PubMed Web of Science ®Google Scholar
• Dalkin BL, Ahmann FR, Nagle R, Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer. J Urol 1996r;155:1357-60
   PubMed Web of Science ®Google Scholar
• Aus G, Abrahamsson PA, Ahlgren G, Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int 2002;90:561-6
   PubMed Web of Science ®Google Scholar
• Klotz LH, Goldenberg SL, Jewett MA, Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol 2003;170:791-4
   PubMed Web of Science ®Google Scholar
• Gravina GL, Festuccia C, Galatioto GP, Surgical and biologic outcomes after neoadjuvant bicalutamide treatment in prostate cancer. Urology 2007t;70:728-33
   PubMed Web of Science ®Google Scholar
• Schulman CC, Debruyne FM, Forster G, 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol 2000;38:706-13
   PubMed Web of Science ®Google Scholar
• Yee DS, Lowrance WT, Eastham JA, Long-term follow-up of 3-month neoadjuvant hormone therapy before radical prostatectomy in a randomized trial. BJU Int 2010;105:185-90
   PubMed Web of Science ®Google Scholar
• Labrie F, Cusan L, Gomez JL, Neoadjuvant hormonal therapy: the Canadian experience. Urology 1997;49:56-64
   PubMed Web of Science ®Google Scholar
• Soloway MS, Pareek K, Sharifi R, Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 2002;167:112-16
   PubMed Web of Science ®Google Scholar
• Prezioso D, Lotti T, Polito M, Neoadjuvant hormone treatment with leuprolide acetate depot 3.75 mg and cyproterone acetate, before radical prostatectomy: a randomized study. Urol Int 2004;72:189-95
   PubMed Web of Science ®Google Scholar
• Van der Kwast TH, Tetu B, Candas B, Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: three versus six months of endocrine therapy. Urology 1999;53:523-9
   PubMed Web of Science ®Google Scholar
• Bono AV, Pagano F, Montironi R, Effect of complete androgen blockade on pathologic stage and resection margin status of prostate cancer: progress pathology report of the Italian PROSIT study. Urology 2001;57:117-21
   PubMed Web of Science ®Google Scholar
• Selli C, Montironi R, Bono A, Effects of complete androgen blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancer. J Clin Pathol 2002;55:508-13
   PubMed Web of Science ®Google Scholar
• Gleave ME, Goldenberg SL, Chin JL, Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 2001;166:500-6
   PubMed Web of Science ®Google Scholar
• Kumar S, Shelley M, Harrison C, Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 2006;4:CD006019
   Google Scholar
• Pu XY, Wang XH, Wu YL, Comparative study of the impact of 3- versus 8-month neoadjuvant hormonal therapy on outcome of laparoscopic radical prostatectomy. J Cancer Res Clin Oncol 2007;133:555-62
   PubMed Web of Science ®Google Scholar
• Brown JA, Garlitz C, Strup SE, Laparoscopic radical prostatectomy after neoadjuvant hormonal therapy: an apparently safe and effective procedure. J Laparoendosc Adv Surg Tech A 2004;14:335-8
   PubMed Web of Science ®Google Scholar
• Maldonado-Valadez R, Teber D, Erdogru T, The impact of neoadjuvant hormonal therapy on the outcome of laparoscopic radical prostatectomy: a matched pair analysis. J Urol 2006;175:2092-6
   PubMed Web of Science ®Google Scholar
• Dreicer R, Magi-Galluzzi C, Zhou M, Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 2004;63:1138-42
   PubMed Web of Science ®Google Scholar
• Magi-Galluzzi C, Zhou M, Reuther AM, Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study. Cancer 2007;110:1248-54
   PubMed Web of Science ®Google Scholar
• Shepard DR, Dreicer R, Garcia J, Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy. J Urol 2009;181:1672-7
   PubMedGoogle Scholar
• Febbo PG, Richie JP, George DJ, Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2005;11:5233-40
   PubMed Web of Science ®Google Scholar
• Garzotto M, Higano CS, O'Brien C, Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer. Cancer 2010;116:1699-708
   PubMed Web of Science ®Google Scholar
• Kim WY, Whang YE, Pruthi RS, Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: a phase II trial. Urol Oncol 2011;29:608-13
   PubMed Web of Science ®Google Scholar
• Hussain M, Smith DC, El-Rayes BF, Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer. Urology 2003;61:774-80
   PubMed Web of Science ®Google Scholar
• Friedman J, Dunn RL, Wood D, Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer. J Urol 2008;179:911-15
   PubMed Web of Science ®Google Scholar
• Womble PR, VanVeldhuizen PJ, Nisbet AA, A phase II clinical trial of neoadjuvant ketoconazole and docetaxel chemotherapy before radical prostatectomy in high risk patients. J Urol 2011;186:882-7
   PubMed Web of Science ®Google Scholar
• Clark PE, Peereboom DM, Dreicer R, Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology 2001;57:281-5
   PubMed Web of Science ®Google Scholar
• Garcia JA, Klein EA, Magi-Galluzzi C, Clinical and biological effects of neoadjuvant sargramostim and thalidomide in patients with locally advanced prostate carcinoma. Clin Cancer Res 2008;14:3052-9
   PubMed Web of Science ®Google Scholar
• Prayer-Galetti T, Sacco E, Pagano F, Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with nonmetastatic high-risk prostate cancer. BJU Int 2007;100:274-80
   PubMed Web of Science ®Google Scholar
• Sella A, Zisman A, Kovel S, Neoadjuvant chemohormonal therapy in poor-prognosis localized prostate cancer. Urology 2008;71:323-7
   PubMed Web of Science ®Google Scholar
• Narita S, Tsuchiya N, Kumazawa T, Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer. World J Surg Oncol 2012;10:1
   PubMed Web of Science ®Google Scholar
• Chi KN, Chin JL, Winquist E, Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol 2008;180:565-70
   PubMed Web of Science ®Google Scholar
• Mellado B, Font A, Alcaraz A, Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer. Br J Cancer 2009;101:1248-52
   PubMed Web of Science ®Google Scholar
• Konety BR, Eastham JA, Reuter VE, Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study. J Urol 2004;171:709-13
   PubMed Web of Science ®Google Scholar
• Pettaway CA, Pisters LL, Troncoso P, Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. J Clin Oncol 2000;18:1050-7
   PubMed Web of Science ®Google Scholar
• Ross RW, Galsky MD, Febbo P, Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: A Prostate Cancer Clinical Trials Consortium trial. Cancer 2012; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Vuky J, Porter C, Isacson C, Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer. Cancer 2009;115:784-91
   PubMed Web of Science ®Google Scholar
• Mathew P, Pisters LL, Wood CG, Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer. J Urol 2009;181:81-7
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Heath EI, Walczak JR, Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol 2009;27:4986-93
   PubMed Web of Science ®Google Scholar
• Sooriakumaran P, Coley HM, Fox SB, A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer. Anticancer Res 2009;29:1483-8
   PubMed Web of Science ®Google Scholar
• D'Amico AV, Cote K, Loffredo M, Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 2002;20:4567-73
   PubMedGoogle Scholar
• Messing EM, Manola J, Sarosdy M, Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999;341:1781-8
   PubMed Web of Science ®Google Scholar
• Messing EM, Manola J, Yao J, Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7:472-9
   PubMed Web of Science ®Google Scholar
• Boorjian SA, Thompson RH, Siddiqui S, Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol 2007;178:864-70
   PubMed Web of Science ®Google Scholar
• Wirth MP, Weissbach L, Marx FJ, Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer. Eur Urol 2004;45:267-70
   PubMed Web of Science ®Google Scholar
• Shelley MD, Kumar S, Coles B, Adjuvant hormone therapy for localised and locally advanced prostate carcinoma: a systematic review and meta-analysis of randomised trials. Cancer Treat Rev 2009;35:540-6
   PubMed Web of Science ®Google Scholar
• McLeod DG, Iversen P, See WA, Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006;97:247-54
   PubMed Web of Science ®Google Scholar
• Iversen P, McLeod DG, See WA, Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. BJU Int 2010;105:1074-81
   PubMed Web of Science ®Google Scholar
• Siddiqui SA, Boorjian SA, Inman B, Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. J Urol 2008;179:1830-7
   PubMed Web of Science ®Google Scholar
• Siddiqui SA, Boorjian SA, Blute ML, Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer. BJU Int 2011;107:383-8
   PubMed Web of Science ®Google Scholar
• Bastide C, Rossi D, Lechevallier E, Seminal vesicle invasion: what is the best adjuvant treatment after radical prostatectomy? BJU Int 2012;109:525-30
   PubMed Web of Science ®Google Scholar
• Mamounas EP. NSABP breast cancer clinical trials: recent results and future directions. Clin Med Res 2003;1:309-26
   PubMedGoogle Scholar
• Montero A, Fossella F, Hortobagyi G, Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 2005;6:229-39
   PubMed Web of Science ®Google Scholar
• Kibel AS, Rosenbaum E, Kattan MW, Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol 2007;177:1777-81
   PubMed Web of Science ®Google Scholar
• Roberts WW, Bergstralh EJ, Blute ML, Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. Urology 2001;57:1033-7
   PubMed Web of Science ®Google Scholar
• Cetnar JP, Malkowicz SB, Palmer SC, Pilot trial of adjuvant paclitaxel plus estramustine in resected high-risk prostate cancer. Urology 2008;71:942-6
   PubMed Web of Science ®Google Scholar
• Ploussard G, Paule B, Salomon L, Pilot trial of adjuvant paclitaxel plus androgen deprivation for patients with high-risk prostate cancer after radical prostatectomy: results on toxicity, side effects and quality-of-life. Prostate Cancer Prostatic Dis 2010;13:97-101
   PubMed Web of Science ®Google Scholar
• Flaig TW, Tangen CM, Hussain MH, Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. J Clin Oncol 2008;26:1532-6
   PubMed Web of Science ®Google Scholar
• Dorff TB, Flaig TW, Tangen CM, Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol 2011;29:2040-5
   PubMed Web of Science ®Google Scholar
• Williams SB, Prasad SM, Weinberg AC, Trends in the care of radical prostatectomy in the United States from 2003 to 2006. BJU Int 2011;108:49-55
   PubMed Web of Science ®Google Scholar
• Bianco FJ Jr, Scardino PT, Eastham JA. Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ("trifecta"). Urology 2005;66:83-94
   PubMed Web of Science ®Google Scholar
• Mottet N, Bellmunt J, Bolla M, EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011;59:572-83
   PubMed Web of Science ®Google Scholar
• D'Amico AV, Whittington R, Malkowicz SB, The combination of preoperative prostate specific antigen and postoperative pathological findings to predict prostate specific antigen outcome in clinically localized prostate cancer. J Urol 1998;160:2096-101
   PubMed Web of Science ®Google Scholar
• Huang Y, Isharwal S, Haese A, Prediction of patient-specific risk and percentile cohort risk of pathological stage outcome using continuous prostate-specific antigen measurement, clinical stage and biopsy Gleason score. BJU Int 2011;107:1562-9
   PubMed Web of Science ®Google Scholar
• Gibbons RP. Total prostatectomy for clinically localized prostate cancer: long-term surgical results and current morbidity. NCI Monogr 1988(7):123-6
   PubMedGoogle Scholar
• Pound CR, Partin AW, Epstein JI, Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 1997;24:395-406
   PubMed Web of Science ®Google Scholar
• Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate 1941. J Urol 2002;167:948-51
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Tangen CM, Hussain MH, Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Ankerst DP, Jiang CS, Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 2006;98:516-21
   PubMedGoogle Scholar
• Tannock IF, de Wit R, Berry WR, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Halabi S, Conaway M, Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999;17:2506-13
   PubMed Web of Science ®Google Scholar
• Beer TM, Bernstein GT, Corman JM, Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Clin Cancer Res 2011;17:4558-67
   PubMed Web of Science ®Google Scholar